Clinical Trial Update: Lenalidomide in Improving Immune Response to Vaccine Therapy in Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Monoclonal B Cell Lymphocytosis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating lenalidomide to enhance immune response to vaccine therapy in patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, o…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Monoclonal B-cell Lymphocytosis
• Small Lymphocytic Lymphoma

Drugs mentioned

• Lenalidomide (lenalidomide)

Snippet

Sponsor: Mayo Clinic | Conditions: Monoclonal B-Cell Lymphocytosis, Stage 0 Chronic Lymphocytic Leukemia | Phase 2 | Status: TERMINATED | Results posted: 2021-01-19